Harnessing Gamma T Cells To Bring Effective Therapies to Patients – Technology Networks

GammaDelta Therapeutics is a company that focusses on utilizing the unique properties of gamma delta () T cells to develop novel immunotherapies for patients.Through their research, the companys scientists have discovered a number of targets and antibodies that have the potential to modulate the activity of T-cells in situ. Therefore, GammaDelta Therapeutics recently announced the formation of Adaptate Biotherapeutics, a spin-out company that will focus on research in this area.

Technology Networks spoke with Natalie Mount, CEO of Adaptate BioTherapeutics, to learn more about the company's aims and the challenges faced when developing immunotherapies and advancing them into clinical studies.

Molly Campbell (MC) Please can you tell us more about T-cell based cell therapy products and their potential applications?Natalie Mount (NM): T cells play an increasingly appreciated critical role in immune surveillance, being able to recognize malignant/transformed cells through a pattern of stress markers. The recognition mechanism is not major histocompatibility complex (MHC) restricted and not dependent on a single antigen.

T cells therefore have potential in a range of disease indications, including both hematological and solid malignancies and a positive correlation between T cell infiltration and prognosis/survival in patients has been determined in a range of oncology indications in studies published in the literature by other groups. Additionally, as a cell therapy, T cells can be used in an allogeneic setting (ie, T cells can be used for unrelated recipients without a requirement for matching).

Both Adaptate Biotherapeutics and GammaDelta Therapeutics are focussed on harnessing the potential of T cells, in particular the V1 subtype which is the predominant T cell type in tissue.This is based on data originating from the labs of Professor Adrian Hayday of Kings College London and the Crick Institute, supported by Cancer Research Technology and also from Professor Bruno Silva Santos of Institute for Molecular Medicine at the University of Lisbon, Portugal.

Previous clinical trials conducted by other groups/companies targeting or using T cells in cancer have focussed on the V2 subtype which is predominant in the blood. These trials have demonstrated safety, but efficacy has been limited.Compared to V2 cells, V1 cells, which are the focus of work at Adaptate Biotherapeutics and GammaDelta Therapeutics, are less susceptible to exhaustion and activation induced cell death. Expansion of donor derived V1 has been shown to be a positive prognostic indicator for acute myeloid leukemia patients following hematopoietic stem cell transplant.

MC: Why are current immunotherapy treatment approaches limited?NM: Immunotherapy approaches have had very significant success and impact in Oncology recently, however, challenges and unmet needs remain.One challenge is effective treatment of solid tumors. The hypoxic, low nutrient tumor environment provides a challenge for successful infiltration and activation of T cells. However, V1 T cells have real potential as they are naturally tissue resident and hence primed for this environment. In addition, their ability to recognize malignant cells by a pattern of markers expressed by dysregulated, transformed cells rather than one specific antigen presented by the MHC provides an additional advantage for both specificity of response and maintenance of efficacy.

T cells act as orchestrators of an immune response and, following recognition of a cell as malignant, they induce maturation of monocytes and signal to alpha beta T cells, hence increasing immunogenicity of the tumor and providing a sustained response, with potential even in tumors with low mutational load which have proven challenging with other immunotherapies.

MC: The new spin-out company, Adaptate Biotherapeutics, will build on GammaDelta's knowledge to modulate T-cell activity using therapeutic antibodies. Why have you decided to create a spin-out focusing on this area of research?NM: GammaDelta Therapeutics was formed in 2016 to harness the unique properties of T cells, and since then has gained extensive knowledge of T-cell biology. In addition to gaining insight into cell growth and isolation, the companys scientists have also discovered a number of targets and antibodies that have potential to modulate the activity of T-cells in situ.

GammaDelta Therapeutics now has a pipeline of cell therapy products progressing into clinical development under the guidance of CEO, Dr Paolo Paoletti.

Adaptate Biotherapeutics will be developing antibodies which will be administered to cancer patients to modulate activity of the patient's gamma delta T cells in situ.

Delivery of cell therapy and antibody therapeutics each needs focus and specific skillsets and formation of two independent entities will facilitate this. The two companies share a common goal to harness the potential of T cells to bring effective therapies to patients. Both benefit from support of the scientific founding team and have common investors, Abingworth and Takeda Pharmaceuticals.MC; Your goal is to develop targets and antibodies that can modulate the activity of T-cells and advance them into clinical studies. What challenges exist here, and how do you hope to overcome them?

Our assets at Adaptate Biotherapeutics are currently at the pre-clinical stage and therefore face the non-clinical development risks for a novel therapy. However, these risks are mitigated by biology understanding from our scientific founders and the work at GammaDelta Therapeutics to date.

One of our challenges is in selecting the most suitable patient population for initial trials. There is potential for opportunity for our therapeutics in multiple indications but the utility of animal models in modelling the human immune compartment and human tumor setting is limited. Therefore in vitro and ex vivo models are important, in addition to the learnings from other clinical studies.

MC: GammaDelta Therapeutics formed in 2016 to gain extensive knowledge of T-cell biology and to developing a portfolio of investigational cell therapies. Some of these cell therapies are poised to enter clinical development. Can you tell us any further information about these therapies?NM: GammaDelta was set up to develop cell-based therapy utilizing ex-vivo expanded tissue resident gd T cells. Subsequent acquisition of Lymphact SAS allowed GammaDelta to augment its capabilities with a platform for ex-vivo expansion of blood derived V1 cells. GammaDelta is focussed on progressing ex-vivo expanded skin and blood derived V1 cells to the clinic both in unengineered and engineered formats. Clinical trials are currently on track to commence in the next 12-18 months.

MC: Your press release states: "The two companies will continue sharing their insights into T-cell biology as they work towards developing different therapeutic modalities". How will you continue to share insights here?NM: Antibodies and cells represent complementary approaches to realizing the potential of T cell activity for patients with solid and haematological malignancies.

The two companies will work together in areas of common interest in the biology of these fascinating cells, such as understanding the phenotype and behavior of T cells in tumors and mechanisms of cell regulation as well as the effects of antibody on the T cells.

We have deliberately established a contractual framework that allows efficient collaboration between scientists of both the companies via formal and informal meetings.

MC: What are your hopes for the future of Adaptate Biotherapeutics?NM: This is a remarkable time in the development of new immune therapies, and the role of "non-conventional" cell types of the immune system is coming to the fore as we recognize the successes achieved to date and the needs of patients and related scientific challenges that remain.

Both GammaDelta Therapeutics and Adaptate Biotherapeutics are at the lead of translating our increasing understanding of T cell biology and its potential into therapies to address these unmet needs.

Adaptate Biotherapeutics has a fantastic opportunity to build and accelerate a portfolio of antibody-based approaches in this novel area and I look forward to the successful translation of this science into therapies with the support of our investors at Abingworth and Takeda Pharmaceuticals.

Dr Natalie Mount, CEO of Adaptate Biotherapeutics was speaking with Molly Campbell, Science Writer, Technology Networks.

See the article here:
Harnessing Gamma T Cells To Bring Effective Therapies to Patients - Technology Networks

How Flight Feathers Evolved: Study of Chickens, Ostriches, Penguins, Ducks and Eagles – SciTechDaily

This picture shows a spirited flying Taiwan Blue Magpie displaying a full array of flight feathers in action. Credit: Shao Huan Lang

If you took a careful look at the feathers on a chicken, youd find many different forms within the same birdeven within a single feather. The diversity of feather shapes and functions expands vastly when you consider the feathers of birds ranging from ostriches to penguins to hummingbirds. Now, researchers reporting in the journal Cell on November 27, 2019, have taken a multidisciplinary approach to understanding how all those feathers get made.

We always wonder how birds can fly and in different ways, says corresponding author Cheng-Ming Chuong of the University of Southern California, Los Angeles. Some soar like eagles, while others require rapid flapping of wings like hummingbirds. Some birds, including ostriches and penguins, dont fly at all.

This picture shows a the asymmetric vane and tapering main shaft of a single flight feather from a goshawk. Credit: Hao Howard Wu and Wen Tau Juan

Such differences in flight styles are largely due to the characteristics of their flight feathers, Chuong adds. We wanted to learn how flight feathers are made so we can understand nature better and learn principles of bioinspired architecture.

In the new study, the researchers put together a multidisciplinary team to look at feathers in many different ways, from their biophysical properties to the underlying molecular biology that allows their formation from stem cells in the skin. They examined the feathers of flightless ostriches, short-distance flying chickens, soaring ducks and eagles, and high-frequency flying sparrows. They studied the extremes by including hummingbirds and penguins. To better understand how feathers have evolved and changed over evolutionary time, the team also looked to feathers that are nearly 100 million years old, found embedded and preserved in amber in Myanmar.

Based on their findings, the researchers explain that feathers modular structure allowed birds to adapt over evolutionary time, helping them to succeed in the many different environments in which birds live today. Their structure also allows for the specialization of feathers in different parts of an individual birds body.

The flight feather is made of two highly adaptable architectural modules: the central shaft, or rachis, and the peripheral vane. The rachis is a composite beam made of a porous medulla that keeps feathers light surrounded by a rigid cortex that adds strength. Their studies show that these two components of the rachis allow for highly flexible designs that enabled to fly or otherwise get around in different ways. The researchers also revealed the underlying molecular signals, including Bmp and Ski, that guide the development of those design features.

Attached to the rachis is the feather vane. The vane is the part of the feather made up of many soft barbs that zip together. The researchers report that the vane develops using principles akin to paper cutting. As such, a single epithelial sheet produces a series of diverse, branched designs with individual barbs, each bearing many tiny hooklets that hold the vane together into a plane using a Velcro-like mechanism. Their studies show that gradients in another signaling pathway (Wnt2b) play an important role in the formation of those barbs.

To look back in time, the researchers studied recently discovered amber fossils, allowing them to explore delicate, three-dimensional feather structures. Their studies show that ancient feathers had the same basic architecture but with more primitive characteristics. For instance, adjacent barbs formed the vane with overlapping barbules, without the Velcro-like, hooklet mechanism found in living birds.

Weve learned how a simple skin can be transformed into a feather, how a prototypic feather structure can be transformed into downy, contour, or flight feathers, and how a flight feather can be modulated to adapt to different flight modes required for different living environments, Chuong says. In every corner and at different morphological scales, we were amazed at how the elegant adaption of the prototype architecture can help different birds to adapt to different new environments.

The researchers say that, in addition to helping to understand how birds have adapted over time, they hope these bioinspired architectural principles theyve uncovered can be useful in future technology design. They note that composite materials of the future could contribute toward the construction of light but robust flying drones, durable and resilient wind turbines, or better medical implants and prosthetic devices.

Team co-leader and biophysicist Wen Tau Juan of the Integrative Stem Cell Center of China Medical University Hospital, Taiwan, has already begun to explore the application of feather-inspired architectural principles in bio-material design. The team also hopes to learn even more about the molecular signals that allow the formation of such complex feather structures from epidermal stem cells that all start out the same.


Reference: The Making of a Flight Feather: Bio-architectural Principles and Adaptation by Wei-Ling Chang, Hao Wu, Yu-Kun Chiu, Shuo Wang, Ting-Xin Jiang, Zhong-Lai Luo, Yen-Cheng Lin, Ang Li, Jui-Ting Hsu, Heng-Li Huang, How-Jen Gu, Tse-Yu Lin, Shun-Min Yang, Tsung-Tse Lee, Yung-Chi Lai, Mingxing Lei, Ming-You Shie, Cheng-Te Yao, Yi-Wen Chen, J.C. Tsai, Shyh-Jou Shieh, Yeu-Kuang Hwu, Hsu-Chen Cheng, Pin-Chi Tang, Shih-Chieh Hung, Chih-Feng Chen, Michael Habib, Randall B. Widelitz, Ping Wu, Wen-Tau Juan and Cheng-Ming Chuong, 27 November 2019, Cell.DOI: 10.1016/j.cell.2019.11.008

This work was supported by the ISCC, CMUH, Taiwan, the Drug Development Center, CMU, Higher Education Sprout Project, Ministry of Education (HESP-MOE), and grants from the National Institutes of Health, Ministry of Science and Technology, Taiwan, iEGG/Avian Genetic Resource/ABC supported by HESP-MOE, the Human Frontier Science Program, the National Natural Science Foundation of China, NSFC, Academia Sinica Research Program on Nanoscience and Nanotechnology, Top Notch Project, NCKU, and a University Advancement grant by MOE, Taiwan.

Read the original:
How Flight Feathers Evolved: Study of Chickens, Ostriches, Penguins, Ducks and Eagles - SciTechDaily

Global Stem Cell Banking Market with Geographic Segmentation, Demand by Regions, Statistical Forecast and Competitive Landscape Research upto…

The Latest forecast study by the Global Markerters.biz has publicized a new report on Global Stem Cell Banking Market, forecasting the analysis from 2019-2026. The report embraces various factors including the overall growth dynamics, market estimation, development prospects across different geographies, and competitive analysis. The preliminary part of the report give a syntactic representation of the market summary, specification, product definition, and objectives.

Request For Free Stem Cell Banking Sample Report (Kindly Use Your Bussiness/Corporate Email Id to Get Priority) https://www.globalmarketers.biz/report/life-sciences/global-stem-cell-banking-market-report-2019,-competitive-landscape,-trends-and-opportunities/135432#request_sample

Key Players of Stem Cell Banking Report are:

CrioestaminalRMS RegrowLifeCellBoyalifeVcanbioKrioEsperiteBeikebiotechCryo-cellPacifiCordCryo StemcellCells4lifePBKM FamiCordStemade BiotechCellsafe Biotech GroupAmericordViaCordCordlife GroupCCBCFamilycordCBRStemCyte

The surveys and interviews get conducted to obtain the newest financial information on Stem Cell Banking are calculated and estimated through various paid secondary sources and hence they are further validated by primary respondents.

We follow a strict research tactics so that our customers should get reliable and accurate information which would help them to make sound business decisions.

Market segments and sub-segments

The geographical analysis covers the following regions:

North America (Canada & U.S.) & Latin America (Mexico, Brazil, Peru, Chile, and others)

Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg) & Eastern Europe (Poland and Russia)

Asia-Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)

Middle-East & Africa (GCC, Southern Africa, and North Africa)

Important aspects of the report

The report is comprised of leading market players information for analyzing the market such as company mug shot, contact details, product collection, production and consumption statistics, sales, revenue, market positions, etc.

A SWOT analysis covers various fundamental facets of the market involving its strengths, weaknesses as well as its external opportunities and threats.

Historic, Current, and forecast of Stem Cell Banking market assessment across various regions for major and evolving market contestants.

Inspects the growth plans, industry policies, market size, value and sales of top Stem Cell Banking players.

Studies crucial factors like market risks, drivers, and maturity analysis.Provides a detailed understanding about the new product inauguration events, mergers, and acquisitions, and competitive growth.

Stem Cell Banking Market Inquiry Here For Detail Report @ https://www.globalmarketers.biz/report/life-sciences/global-stem-cell-banking-market-report-2019,-competitive-landscape,-trends-and-opportunities/135432#inquiry_before_buying

The market is segmented into below points:

Global Stem Cell Banking Market by Type/Products:

Placental Stem Cells (PSCs)Human Embryo-derived Stem Cells (HESCs)Bone Marrow-derived Stem Cells (BMSCs)Adipose Tissue-derived Stem Cells (ADSCs)Dental Pulp-derived Stem Cells (DPSCs)Other Stem Cell Sources

Global Stem Cell Banking Market by Application/End-Use:

Personalized Banking ApplicationsClinical ApplicationsHematopoietic DisordersAutoimmune DisordersOther DiseasesResearch ApplicationsDisease Treatment StudiesLife Science ResearchDrug Discovery

Explore Full Stem Cell Banking Report With Detailed TOC Here @ https://www.globalmarketers.biz/report/life-sciences/global-stem-cell-banking-market-report-2019,-competitive-landscape,-trends-and-opportunities/135432#table_of_contents

About Global Marketers Biz:

Global Marketers is a research eye which discovers the syndicate, custom and consulting research needs. The company surpasses in catering to the research requirements of commercial, industrial and all other business enterprises. Surgical market analysis followed by a Comprehensive research methodology will drive the businesses in planning & reshaping the business schemes and the growth of the industry. The company shows interest in offering researches related to healthcare, chemical, technology, automobile and many of the other areas. This is a trustworthy brand when talked about quality survey and highly reachable to customer requirements of any industry situated across the globe.

For any additional questions get in touch with us

Mr. Alex White

Email: Alex@globalmarketers.biz

Phone number: +1(617)2752538

Website: https://www.globalmarketers.biz/

See more here:
Global Stem Cell Banking Market with Geographic Segmentation, Demand by Regions, Statistical Forecast and Competitive Landscape Research upto...

Global Parkinsons Disease Treatment Market 2019 Analysis by Industry Growth, Size, Share, Trends and Forecast by 2025 – Eastlake Times

Global Parkinsons Disease Treatment Market 2019-2025 Overview

The Parkinsons disease treatment market growth was driven because of increase in the geriatric population and the rise in the occurrence of the Parkinsons disease and the funding for research.

Global Parkinsons disease treatment market is anticipated to experience the substantial growth during the forecast period. Growth in the occurrence of the Parkinsons diseases is projected to supplement the growth of global Parkinsons disease treatment market in the coming future. In addition, the combined treatments supporting in the long action of constant dopaminergic stimulation medicines, neural transplantation and gene therapy is expected to fuel the Parkinsons disease treatment market growth.

Request sample copy of Parkinsons Disease Treatment Market at: https://www.adroitmarketresearch.com/contacts/request-sample/615

Parkinsons disorder is a neurological disorder affecting the movements of body. There are five stages of this disease and can hamper the individuals leg & hand movements, facial expressions getting worse with the growing age. Increase in the elderly population related to the rise in the investments in the activities of research & development, growth in the awareness for healthcare and the neurological disorders are the factors driving the global Parkinsons disease treatment market growth over the forecast period. On the other hand, due to the presence of the other treatments is hampering the Parkinsons disease treatment market growth.

Get 10% Discount:https://www.adroitmarketresearch.com/contacts/discount/615

Current developments in the Parkinsons disease treatment, for example, combined treatment to continue the effect of constant dopaminergic stimulation medicines, gene therapy, neural transplantation, neuroprotective treatment to reduce the disease prediction and support for the neurostimulation tools are estimated to provide large development in the global Parkinsons disease treatment market growth during the forecast period. Moreover, major characteristics that are fueling the requirement and demand for the global parkinsons disease treatment market are prevalence of parkinsons disease and growth in the geriatric population. Two important characteristics that are responsible to boost the Parkinsons disease treatment market development are prevalence of the neurodegenerative syndrome and rise in the elderly population. Although, increase in the medicines in the pipeline and growth in the R&D activities are anticipated to surge the Parkinsons disease treatment market size. In addition, lack of skills for the early diagnosis and large spending on treatment is projected to bolster the development of global Parkinsons disease treatment market.

Key factor driving the growth of Parkinsons disease treatment market is the growth in the acceptance of the treatment for Parkinson disease in healthcare sector. For treating and detecting the dysfunctioning of the human beings central nervous system and the neurological damage because of lack of cells and nerves are the main function of Parkinsons disease treatment market.

Global Parkinsons disease treatment market is segmented into end-use, distribution channel, drug class and region. Based on end-use, market is divided into clinics and hospitals. On the basis of distribution channel, market is divided into retail pharmacies, online pharmacies and hospital. On considering the drug class, market is divided into MAO inhibitors, Levopoda/ Carbidopa and Dopamine Receptor Agonists.

Geographically, regions involved in the development of Parkinsons disease treatment market growth are Europe, North America and Asia Pacific. Asia Pacific is anticipated to show the rapid growth because of the increase in the trend of medical tourism and medical infrastructure. North America holds the largest

Read details of the report athttps://www.adroitmarketresearch.com/industry-reports/parkinsons-disease-treatment-market

Parkinsons disease treatment market share. Europe is dominating the Parkinsons disease treatment market because of the maximum market revenue in the coming years.

Key players involved in the Parkinsons disease treatment market analysis are Teva Pharmaceutical Industries, Novartis AG, Impax Laboratories and GlaxoSmithKline.

Key Segments in the Global Parkinsons Disease Treatment Market are-

By End-Use, market is segmented into:

By Distribution Channel, market is segmented into:

By Drug Class, market is segmented into:

By Regions market is segmented into:

What to expect from the Global Parkinsons Disease Treatment Market report?

Predictions of future made for this market during the forecast period.

Information on the current technologies, trends, devices, procedures, and products in the industry.

Detailed analysis of the market segmentation, depending on the types, devices, and products.

Government regulations and economic factors affecting the growth of the market.

An insight into the leading manufacturers.

Regional demographics of the market.

Who should buy this report?

Venture capitalists, Investors, financial institutions, Analysts, Government organizations, regulatory authorities, policymakers ,researchers, strategy managers, and academic institutions looking for insights into the market to determine future strategies

Else place an Inquire before Purchase Parkinsons Disease Treatment Market Size, Status and Forecast 2025:https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/615

About Us:

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Information:

Ryan Johnson

Account Manager Global

3131 McKinney Ave Ste 600, Dallas,

TX75204, U.S.A.

Phone No.: USA: +1 972-362-8199/ +91 9665341414

Read the original here:
Global Parkinsons Disease Treatment Market 2019 Analysis by Industry Growth, Size, Share, Trends and Forecast by 2025 - Eastlake Times

Medicine of the future: cell technologies in Ukraine – Interfax-Ukraine

How to score a decisive penalty to the disease? A football-player Andrii Shevchenko tells own experience of stem cell treatment

December 3rd, the Institute of Cell Therapy will present in Kiev the first results of the placental stem cells clinical trials in Ukraine in a partnership with the Institute of Traumatology and Orthopedics of NAMS of Ukraine and Kiev Clinical Hospital 6. This time the specialists will focus attention on such prevalent diseases as knee joints arthrosis and joints injuries, in particular in professional athletes. Andrii Shevchenko, a legendary football-player and trainer of the national team of Ukraine will participate in the press-conference.

Cell therapy is an innovative, extremely promising method of diseases and injuries treatment, that allows to restore damaged tissues of the body with the help of the new cells, the stem cells. Stem cells have a unique capability to transform into all types of tissues and cells of the body, in particular the cells of blood, liver, myocardium, cartilaginous or nervous tissue. Courtesy of this they restore damaged organs and their functions.

Knee arthrosis is called the disease of the piano players and athletes. The most frequently this disease affects people, whose body is exposed to the extreme loadings, in particular athletes. The females and males, aged over 50, are also in the risk group, from which almost one third is diagnosed the arthrosis of knee joints. This disease is accompanied by the severe pain, limitations at walking and sometimes even by the total inability to move.

The result of the clinical trials, conducted by the Institute of Cell Therapy in the partnership with the Institute of Traumatology and Orthopedics of NAMS of Ukraine and Kiev Clinical Hospital 6 should become the opportunity to use cell therapy for knee arthrosis treatment, improve of the life quality of the patients, suffering from this pathology as well as to avoid or postpone the surgery on knee joint replacement for the artificial one. Stem cells are used worldwide for the treatment of approximately 100 severe diseases, in some disorders this is the only effective method of therapy.

Institute of Cell Therapy is a hightechnological medical institution, specializing on research, medical services and has the own Centre of Science with a Laboratory for Placenta Stem Cells. The Institute already has the experience of clinical trials performance on cell and tissue drugs, after completion of which the Ministry of Health of Ukraine issued a permission for the use of the tested technology of manufacturing and application of cell/tissue preparations, in particular for the treatment of pancreonecrosis and disorders of lower limbs peripheral arteries with the umbilical cord blood stem cells and autologous adipose tissue.

Today 4 clinical trials on the use of cell and tissue therapy methods are on the final stage and other 4 trials are going on.

The press-conference, devoted to the innovative approach in the therapy of knee joint using placenta stem cells will take place on December 3rd at 11 am at the address: Medical campus, Liubomyr Husar (Kosmonaut Komarov avenue, 3, Institute of Cell Therapy.

Participants of the press-conference are:

1. Mykola Sokolov, MD, PhD, Chief Doctor of the Institute of Cell Therapy, leading specialist in cell technologies.

2. Volodymyr Shablii, PhD, Deputy CEO of the Stem Cells Bank, Chief of the Laboratory for Placenta Stem Cells of the Institute of Cell Therapy. Member of the International Placenta Stem Cell Society.

3. Ievgen Golyuk, MD, PhD, Chief of the Scientific and Practical Centre of Tissue and Cell Therapy of the state institution Institute of Traumatology and Orthopedics of the National Academy of Medical Sciences of Ukraine.

4. Roman Birsa, MD, a physician of the highest qualification category, orthopedist-traumatologist of the Department of Traumatology and Orthopedics, Kiev City Clinical Hospital 6.5. Petro Nemtinov, MD, PhD, a senior researcher of the Coordination Centre of Transplantation of Organs, Tissues and Cells of the Ministry of Health of Ukraine.

Special guest: Andrii Shevchenko, a legendary football player, the chief trainer of the national football team of Ukraine.

Accreditation of journalists is mandatory: office@med-info.com.ua; tel. 098 20 47 59

Read the original post:
Medicine of the future: cell technologies in Ukraine - Interfax-Ukraine

Stem Cell Therapy May Improve Heart Health In New Ways – TheHealthMania

Recently, a new study that appears in the journal Nature, focuses on stem cell therapy and shows unexpected ways in which it may be helpful in recovering the health of the heart. Stem cell therapy has become popular in the past few years due to its benefits for a big number of health conditions.

Currently, there is major ongoing research on stem cells since they are responsible for the regeneration of new cells and may play a fundamental role in understanding the development of a variety of different diseases as well as their potential treatments.

Some of the recent discoveries of medical science include using stem cells as regenerative medicine as they can be turned into particular types of cells that may be able to replace tissues damaged as a result of health issues and thereby control the disease.

Read also:New Study Reveals Hydromethylthionine Slows Cognitive Decline and Brain Atrophy

The therapy can be specifically useful for people with conditions such as type 1 diabetes, spinal cord injuries, Alzheimers disease, Parkinsons disease, stroke, cancer, burns, amyotrophic lateral sclerosis, heart disease, and osteoarthritis.

At the moment, the most successful procedure that involves stem cell therapy is performing a bone marrow transplant. This surgical operation replaces the cells which have been damaged during chemotherapy by programmed stem cells. People are usually able to maintain and live a normal life after recovery from the surgery.

Furthermore, stem cell usage in clinical trials designed for testing the effectiveness, safety, and potential negative impact of new drugs. To do so, the stem cells can be programmed into becoming the type of cells that the drug aims to target.

The new study, which was led by Jeffery Molkentin who is a professor of the Howard Hughes Medical Institute (HHMI) and the director of Molecular Cardiovascular Microbiology a Cincinnati Childrens Hospital Medical Center, takes data from a study from the same journal, Nature, from the years 2014 which was conducted by the same medical team.

In the new paper, the team with Molkentin as the principal investigator found some unexpected results. There were two types of stem cells in the clinical trial cardiac progenitor cells and bone marrow mononuclear cells.

The main objective of the new trial was to re-evaluate the results of the 2014 study, which showed that injecting c-kit positive heart stem in the heart does not help in the regeneration of cardiomyocytes, to see how the cell therapy can be made to be effective.

It was instead discovered that injecting an inert chemical called zymosan, which is designed particularly for inducing an innate immune response, or dead stem cells can also be beneficial for the recovery of heart as they may speed up the healing procedure.

Injecting either dead stem cells or zymosan led to a reduction in the development of cellular matrix connective tissue in the areas which had been damaged in the heart. In addition, the mechanical properties of the targeted scar also improved.

Another important finding was that chemical substances such as zymosan are required to be injected directly into the heart for optimum results. In previous clinical trials, direct injections were avoided for safety reasons.

Molkentin and the team state that follow-up studies and trials on this new discovery are imminent as they may be important for developing therapies in the future.

Continue reading here:
Stem Cell Therapy May Improve Heart Health In New Ways - TheHealthMania

Proof-of-Concept Study of CAR-NK Cell Therapy with Engineered Persistence Shows Potential – Cancer Network

A first-of-kind multi-antigen targeted off-the-shelf chimeric antigen receptor (CAR)-natural killer (NK) cell with engineered persistence has the potential to be a readily available treatment option for patients, Robert A. Brodsky, MD, said in a preview of the 61st American Society of Hematology (ASH) Annual Meeting & Exposition.

As most of you are well aware, CAR T-cell (therapy has) captured the imagination of physician scientists and patients alike, mainly for their incredible efficacy in treating B-cell malignancies like acute lymphocytic leukemia and non-Hodgkin lymphomas, said Brodsky, who serves as secretary of ASH and is also the director of the division of hematology at Johns Hopkins Medicine.

However, he added, this treatment option does not come without its drawbacks: namely, time, expenses, toxicity.

Only about two-thirds of patients enrolled in CAR T-cell trials will actually see infusion because often the disease will progress during the time it takes to make a successful product, Brodsky said.

Therefore, there is a need to develop a more timely infusion that can be associated with lower costs, and hopefully, less toxicity.

At the upcoming ASH Annual Meeting & Exposition, being held from December 7-10 in Orlando, Florida, Jode P. Goodridge, PhD, will present on his teams proof-of-concept study of induced pluripotent stem cell (iPSC)-derived effector cells.

iPSC-derived effector cells offer distinct advantages for immune therapy over existing patient- or donor- derived platforms, both in terms of scalable manufacturing from a renewable starting cellular material and precision genetic engineering that is performed at the single-cell level, the researchers wrote in their abstract. iPSC derived natural killer (iNK) cells offer the further advantage of innate reactivity to stress ligands and MHC downregulation and the potential to recruit downstream adaptive responses.

The candidate, called FT596, is consistently manufactured from a master iPSC line engineered to uniformly express an NK cell-calibrated CD19-targeting CAR, an enhanced functioning high-affinity, non-cleavable CD16, and a recombinant fusion of IL-15 and IL-15 receptor alpha for cytokine-autonomous persistence, according to the abstract.

What the authors here did is take advantage of the use of induced pluripotent stem cells and differentiated them to natural killer cells. Natural killer cells are not T cells but they are another form of lymphocytes that can be very effective in killing cancer cells. What they did is they engineered these pluripotent stem cells to target B cells, and they are specifically targeting the CD19 antigen on B cells and showing that these are very effective in cell line models and animal models, explained Brodsky.

However, of note, this product has not been tested in humans yet.

The big advance here is that this offers the potential of having a readily available source of basically CAR-NK cells that wouldnt need time to grow them up before they would be infused, Brodsky concluded.

Goodridge JP, Mahmood S, Zhu H, et al. FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies. Presented at: 61st ASH Annual Meeting & Exposition Meeting preview; to be presented December 7, 2019; Orlando, Fla. Abstract 301.

The rest is here:
Proof-of-Concept Study of CAR-NK Cell Therapy with Engineered Persistence Shows Potential - Cancer Network

Mum shares heartbreaking photo of toddler sobbing through gruelling cancer treatment – The Sun

THIS is the heartbreaking moment a tiny toddler sobs her way through agonising cancer treatment.

Sophia Soto's devastated mum took the photo while her little 14-month-old was having a lead put on her chest.


Sophia was diagnosed with stage 4 neuroblastomaafter tumours were discovered behind her eyes and on her kidney.

And her mum Rosie, 40, is now sharing the harrowing image in a bid to highlight the traumatic reality of childhood cancer.

Speaking about the poignant picture, Rosie, from Florida, USA, said: "The picture of Sophia upset really does home in on the reality of childhood cancer.

"She was having a lead put on her chest for her treatment - which she didn't want - hence why Sophia was so upset.



"I look back at the picture now and wonder how I did it; it was so hard watching my little girl so ill."

Rosie first suspected something was wrong with Sophia after she began developing bruising around her eyes - something she claims doctors repeatedly dismissed as being from bump or fall.

It wasn't until Rosie took Sophia to see an eye specialist that they spotted what they suspected tumours behind her eyes were causing the bruising.

Rosie added: "Sophia kept getting bruising on her eyes and I didn't recall her falling over or anything, so I didn't understand where they were come from.



"I kept taking her to the doctors because the bruising wasn't going away, but they just said it must have been from a bump or something.

"Sophia wasn't referred for a scan or biopsy until I went to see an eye specialist with her who knew straight away that it was caused by a tumour.

"She was sent for an MRI where black spots appeared on the scans confirming the tumours behind her eyes.

"It was then the biopsy which found the tumours on one of her kidneys as well which led to her stage 4 neuroblastoma diagnosis."

Neuroblastoma is a rare type of cancer that mostly affects babies and children and develops from specialised nerve cells left behind from a baby's development in the womb.

I kept taking her to the doctors because the bruising wasn't going away, but they just said it must have been from a bump or something

After being diagnosed in March 2014, the then 14-month-old endured 60 rounds of chemotherapy, 20 rounds of radiation and a stem cell transplant over a six months period.

Thankfully, Sophia, now six, has been in remission for five years and now looks like a completely different child compared to the one in the heart wrenching photograph.

She was told she was in remission in November 2014 and has been medication free for two years.

Sophia isn't yet classified as 'cancer free' so still goes for check ups every six months with specialists.

What are the symptoms of cancer in children?

Cancer symptoms can be very similar to those of other childhood illnesses - and they vary between children.

According toCancer Research UK, there are 15 signs to look out for:



The brave six-year-old still has tumours behind her eyes which cannot be removed due to the placement of them, but doctors believe the tumours are benign and therefore not causing Sophia too much harm.

Rosie added: "Doctors are reluctant to remove the tumours Sophia currently has behind her eyes as they've said it would be likely the surgery to disfigure her face.

"Whilst they are tumours, doctors are reasonably confident that they are not cancerous so we have decided to not have the surgery right now, but it may be something she has when she's older."



Sophia now looks like any other fun-loving child and from her appearance, you would never know she had cancer.

The six-year-old loves to dance and hopes of becoming a vet one day.

Rosie said: "No one can imagine what she went through looking at her now - she just looks like a normal regular child.

"Sophia has her moments when she asks about when she was sick and has questions about her treatment scars, but over all she's a pretty happy girl.




SURGE IN CASES Every 90 secs someone is told they have cancer - 10 signs you need to know


PRISONER IN MY HOME I live like a vampire after cancer ate my nose as I worry I scare kids

DIY SOS Prostate cancer home pee test 'detects it 5 years earlier & could save thousands'

LAST HOPE I've got months to live after dismissing terminal cancer as a niggling cough

OUT OF TIME Mum died 3 hours before my wedding after I brought it forward so she'd be there

MISSED CHANCES Docs said our little girl was 'attention seeking' but it was a brain tumour

NAIL IT The 'diamond gap' finger test that could be an early warning sign of lung cancer

BRIDE'S DREAM Cancer-stricken bride had arm amputated to have enough time to get married

LOCK OF LOVE Mum lets four-year-old daughter cut her hair before it falls out from chemo

"If I was to say anything to other parents with children battling cancer, I'd say to them to not give up, stay positive and keep your faith.

"It's really important not to compare your child's process to anyone else as everyone battles illnesses differently as every situation is different.

"We're over the moon that Sophia is now doing so well - we're really blessed that she's such a fighter."


Here is the original post:
Mum shares heartbreaking photo of toddler sobbing through gruelling cancer treatment - The Sun

Bone Therapeutics SA: Information on the total number of voting rights and shares – GlobeNewswire

Regulated information

Gosselies, Belgium, 29November 2019, 7am CET BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the development of innovative cell and biological therapies to address high unmet medical needs in orthopaedics and bone diseases, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares on 14November 2019 following the conversion of convertible bonds issued on the private placement on 7March 2018. The following information is published in accordance with Article15 of the Belgian Law of 2May 2007 on the publication of major shareholdings in issuers whose shares are admitted to trading on regulated market.

(1) Based on the conversion price of EUR3.3971 (92% of the Volume-Weighted-Averaged-Price of Bone Therapeutics shares on 14November 2019).

About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy and an innovative biological product in later-stage clinical development across a number of disease areas, which target markets with large unmet medical needs and limited innovation.

Bone Therapeutics core technology is based on its allogeneic cell therapy platform (ALLOB) which uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery, and are produced via a proprietary, cutting-edge manufacturing process.

The Companys ALLOB product pipeline includes a cell therapy product candidate that is expected to enter PhaseIIb clinical development for the treatment of difficult-to-heal fractures and a PhaseII asset in patients undergoing a spinal fusion procedure. In addition, the Company is also developing an off-the-shelf protein solution, JTA-004, which is expected to enter PhaseIII development for the treatment of pain in knee osteoarthritis.

Bone Therapeutics cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. Further information is available at http://www.bonetherapeutics.com.


Bone Therapeutics SAThomas Lienard, Chief Executive OfficerJean-Luc Vandebroek, Chief Financial OfficerTel: +32 (0) 71 12 10 00investorrelations@bonetherapeutics.com

International Media Enquiries:Consilium Strategic CommunicationsMarieke VermeerschTel: +44 (0) 20 3709 5701bonetherapeutics@consilium-comms.com

For French Media and Investor Enquiries:NewCap Investor Relations & Financial CommunicationsPierre Laurent, Louis-Victor Delouvrier and Arthur RouillTel: + 33 (0)1 44 71 94 94bone@newcap.eu

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors` current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person`s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

See more here:
Bone Therapeutics SA: Information on the total number of voting rights and shares - GlobeNewswire

Mesenchymal Stem Cells Market Key Trends, Key Players, Challenges And Standardization, Analysis Of Key Players, And Forecast To 2026 – WindStreetz

The Global Mesenchymal Stem Cells Market covers explicit data considering the advancement rate, advertise gauges, drivers, confinements, future based interest, and income during the figure time frame. Further, the report comprises information amassed from various primary and secondary sources.

Request your Sample PDF Report: @ https://www.alexareports.com/report-sample/10268

The mesenchymal stem cells market is anticipated to grow at a CAGR of 7.0% from 2018 to 2026 according to a new research report published by Alexa Reports Research. The market was valued at USD 1,335.1 million in 2017 and is estimated to reach USD 2,518.5 Million by 2026. In 2017, the drug discovery application dominated the market, in terms of revenue. North America region is observed to be the leading contributor in the global market revenue in 2017.

Mesenchymal stem cells are adult stem cells, which are traditionally found in the bone marrow. However, they can also be parted from other available tissues including peripheral blood, cord blood, fallopian tube. These stem cells mainly function for the replacement of damaged cell and tissues. The potential of these cell is to heal the damaged tissue with no pain to the individual. Scientists are majorly focusing on developing new and innovative treatment options for the various chronic diseases like cancer. Additionally, the local governments have also taken various steps for promoting the use of these stem cells.

The global mesenchymal stem cells market growth is primarily driven by the increasing demand for these stem cells as an effective treatment alternative for knee replacement in the recent past.

To Enquire About This Comprehensive Report, Click Here@ https://www.alexareports.com/send-an-enquiry/10268

Furthermore, increasing elderly population across the globe, and rising prevalence of various chronic diseases including cancer, autoimmune diseases, bone and cartilage diseases are factors expected to boost the market growth during the forecast period. In addition, effective government policies, and funding for research and development would positively influence the market growth over coming years. However, some of the political point of views, and higher cost of treatment by using mesenchymal stem cells might restraint the growth during the forecast period.

Increasing demand for better healthcare facilities, rising geriatric population across the globe, and continuous research and development activities in this area by the key players is expected to have a positive impact on the growth of Mesenchymal Stem Cells market. North America generated the highest revenue in 2017, and is expected to be the leading region globally during the forecast period. The Asia Pacific market is also expected to witness significant market growth in coming years. Developing healthcare infrastructure among countries such as China, India in this region is observed to be the major factor promoting the growth of this market during the forecast period.

The major key players operating in the industry are Cell Applications, Inc., Cyagen Biosciences Inc. Axol Bioscience Ltd., Cytori Therapeutics Inc., Stem cell technologies Inc., Celprogen, Inc. BrainStorm Cell Therapeutics, Stemedica Cell Technologies, Inc. These companies launch new products and undertake strategic collaboration and partnerships with other companies in this market to expand presence and to meet the increasing needs and requirements of consumers.

Click Here To Get Exclusive Discount @ https://www.alexareports.com/check-discount/10268

Thank you for your time. You can also ask for individual chapter wise or section or region wise report version.

About Us:Alexa Reports is a globally celebrated premium market research service provider, with a strong legacy of empowering business with years of experience. We help our clients by implementing decision support system through progressive statistical surveying, in-depth market analysis, and reliable forecast data. Alexa Reports is a globally celebrated premium market research service provider, with a strong legacy of empowering business with years of experience. We help our clients by implementing decision support system through progressive statistical surveying, in-depth market analysis, and reliable forecast data.

Contact Us:Alexa ReportsPh no: +1-408-844-4624 / +91- 7030626939Email: sales@alexareports.comSite: https://www.alexareports.com

Read the rest here:
Mesenchymal Stem Cells Market Key Trends, Key Players, Challenges And Standardization, Analysis Of Key Players, And Forecast To 2026 - WindStreetz